心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

《2020年加拿大心脏淀粉样变性患者评估和治疗的联合立场声明》解读

2020-08-11 心电与循环.2020.39(4):321-325.

心脏淀粉样

2020 年3 月加拿大心血管学会联合加拿大心力衰竭学会在《Canadian Journal of Cardiology》发表了《心脏淀粉样变性患者评估和治疗的联合立场声明》（下称声明）。这是全球首次

中文标题：

《2020年加拿大心脏淀粉样变性患者评估和治疗的联合立场声明》解读

发布机构：

发布日期：

2020-08-11

简要介绍：

2020 年3 月加拿大心血管学会联合加拿大心力衰竭学会在《Canadian Journal of Cardiology》发表了《心脏淀粉样变性患者评估和治疗的联合立场声明》（下称声明）。这是全球首次国家级别心血管专业组织就CA 患者的流行病学、临床诊断和治疗进行的较为全面的总结，并为该疾病的诊治提供依据，本文就其重点内容进行解读。

相关资料下载：
[AttachmentFileName(sort=1, fileName=_2020年加拿大心脏淀粉样变性_省略_者评估和治疗的联合立场声明_解读_潘小宏.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b4d2e1c0019539d2, title=《2020年加拿大心脏淀粉样变性患者评估和治疗的联合立场声明》解读, enTitle=, guiderFrom=心电与循环.2020.39(4):321-325., authorId=0, author=, summary=2020 年3 月加拿大心血管学会联合加拿大心力衰竭学会在《Canadian Journal of Cardiology》发表了《心脏淀粉样变性患者评估和治疗的联合立场声明》（下称声明）。这是全球首次, cover=https://img.medsci.cn/2020817/1597678085934_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Tue Aug 11 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #333333;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020 年3 月加拿大心血管学会联合加拿大心力衰竭学会在《Canadian Journal of Cardiology》发表了《心脏淀粉样变性患者评估和治疗的联合立场声明》（下称声明）。这是全球首次国家级别心血管专业组织就CA 患者的流行病学、临床诊断和治疗进行的较为全面的总结，并为该疾病的诊治提供依据，本文就其重点内容进行解读。</p> </div> </div> </div>, tagList=[TagDto(tagId=106059, tagName=心脏淀粉样)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=17739, guiderKeyword=心脏淀粉样变, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=5, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2119, appHits=159, showAppHits=0, pcHits=436, showPcHits=1960, likes=4, shares=18, comments=22, approvalStatus=1, publishedTime=Mon Aug 17 23:41:12 CST 2020, publishedTimeString=2020-08-11, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 17 23:28:10 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 01:01:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_2020年加拿大心脏淀粉样变性_省略_者评估和治疗的联合立场声明_解读_潘小宏.pdf)])
_2020年加拿大心脏淀粉样变性_省略_者评估和治疗的联合立场声明_解读_潘小宏.pdf
下载请点击：
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=920886, encodeId=ea5092088658, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a85158611, createdName=146aff40m92暂无昵称, createdTime=Fri Jan 29 01:17:55 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901504, encodeId=47d5901504d3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fc089965, createdName=wxt0426, createdTime=Mon Nov 23 17:22:48 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900269, encodeId=321f90026945, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Wed Nov 18 20:18:42 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889571, encodeId=7b388895e19b, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f01326278, createdName=704078480, createdTime=Thu Oct 01 12:02:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888770, encodeId=bfac888e7006, content=这个不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200811/34935bf531b24fcc9ad97977f261b84d/258bb5c512754458868fca3f28f1061b.jpg, createdBy=ef545410182, createdName=新手区新手, createdTime=Sun Sep 27 18:03:01 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2021-01-29 146aff40m92暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=920886, encodeId=ea5092088658, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a85158611, createdName=146aff40m92暂无昵称, createdTime=Fri Jan 29 01:17:55 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901504, encodeId=47d5901504d3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fc089965, createdName=wxt0426, createdTime=Mon Nov 23 17:22:48 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900269, encodeId=321f90026945, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Wed Nov 18 20:18:42 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889571, encodeId=7b388895e19b, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f01326278, createdName=704078480, createdTime=Thu Oct 01 12:02:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888770, encodeId=bfac888e7006, content=这个不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200811/34935bf531b24fcc9ad97977f261b84d/258bb5c512754458868fca3f28f1061b.jpg, createdBy=ef545410182, createdName=新手区新手, createdTime=Sun Sep 27 18:03:01 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2020-11-23 wxt0426

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=920886, encodeId=ea5092088658, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a85158611, createdName=146aff40m92暂无昵称, createdTime=Fri Jan 29 01:17:55 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901504, encodeId=47d5901504d3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fc089965, createdName=wxt0426, createdTime=Mon Nov 23 17:22:48 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900269, encodeId=321f90026945, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Wed Nov 18 20:18:42 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889571, encodeId=7b388895e19b, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f01326278, createdName=704078480, createdTime=Thu Oct 01 12:02:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888770, encodeId=bfac888e7006, content=这个不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200811/34935bf531b24fcc9ad97977f261b84d/258bb5c512754458868fca3f28f1061b.jpg, createdBy=ef545410182, createdName=新手区新手, createdTime=Sun Sep 27 18:03:01 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2020-11-18 1480b553m56(暂无昵称)

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=920886, encodeId=ea5092088658, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a85158611, createdName=146aff40m92暂无昵称, createdTime=Fri Jan 29 01:17:55 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901504, encodeId=47d5901504d3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fc089965, createdName=wxt0426, createdTime=Mon Nov 23 17:22:48 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900269, encodeId=321f90026945, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Wed Nov 18 20:18:42 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889571, encodeId=7b388895e19b, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f01326278, createdName=704078480, createdTime=Thu Oct 01 12:02:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888770, encodeId=bfac888e7006, content=这个不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200811/34935bf531b24fcc9ad97977f261b84d/258bb5c512754458868fca3f28f1061b.jpg, createdBy=ef545410182, createdName=新手区新手, createdTime=Sun Sep 27 18:03:01 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2020-10-01 704078480

    好东西，谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=920886, encodeId=ea5092088658, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=06a85158611, createdName=146aff40m92暂无昵称, createdTime=Fri Jan 29 01:17:55 CST 2021, time=2021-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901504, encodeId=47d5901504d3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fc089965, createdName=wxt0426, createdTime=Mon Nov 23 17:22:48 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900269, encodeId=321f90026945, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0975264133, createdName=1480b553m56(暂无昵称), createdTime=Wed Nov 18 20:18:42 CST 2020, time=2020-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=889571, encodeId=7b388895e19b, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3f01326278, createdName=704078480, createdTime=Thu Oct 01 12:02:18 CST 2020, time=2020-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=888770, encodeId=bfac888e7006, content=这个不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200811/34935bf531b24fcc9ad97977f261b84d/258bb5c512754458868fca3f28f1061b.jpg, createdBy=ef545410182, createdName=新手区新手, createdTime=Sun Sep 27 18:03:01 CST 2020, time=2020-09-27, status=1, ipAttribution=)]
    2020-09-27 新手区新手

    这个不错

    0

以上为热门评论，梅斯医学App还有更多内容

拓展阅读

转甲状腺素蛋白心脏淀粉样变诊断与治疗中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2021-04-30

2023 ACC专家共识决策路径：心脏淀粉样变患者的综合多学科护理

美国心脏病学会(ACC,American College of Cardiology) · 2023-01-14

2023台湾心脏病学会关于心脏淀粉样变性诊断与治疗的专家共识

台湾心脏病学会(TSOC,Taiwan Society of Cardiology) · 2023-07-17